Table 1.
Patient numbers, follow-up time, episodes of loss to follow-up (LTFU) and crude rates of LTFU by characteristic categories for patients enrolled in the Australian HIV Observational database between 1999 and 2013 with over 1 year of follow-up1
| N (%) | Person years (PY) | LTFU | Rate (95% CI) per 100 PY | ||
|---|---|---|---|---|---|
| All | 3,413 (100.00) | 23,922 | 2,349 | 9.82 (9.43–10.22) | |
| Sex | |||||
| Male | 3,208 (94.0) | 22,620 | 2,241 | 9.91 (9.51–10.33) | |
| Female | 205 (6.0) | 1,302 | 108 | 8.30 (6.87–10.02) | |
| Age2 | |||||
| Mean (SD) | 42.3 (10.2) | ||||
| <30 | 321 (9.4) | 656 | 144 | 21.95 (18.64–25.84) | |
| 30–39 | 1,247 (36.5) | 5,240 | 737 | 14.06 (13.08–15.12) | |
| 40–49 | 1,126 (33.0) | 9,089 | 881 | 9.69 (9.07–10.36) | |
| 50–59 | 519 (15.2) | 5,997 | 427 | 7.12 (6.48–7.83) | |
| 60–69 | 164 (4.8) | 2,407 | 128 | 5.32 (4.47–6.32) | |
| ≥70 | 36 (1.1) | 532 | 32 | 6.01 (4.25–8.5) | |
| Exposure | |||||
| MSM | 2,581 (75.6) | 18,566 | 1,783 | 9.60 (9.17–10.06) | |
| IDU | 209 (6.1) | 1,301 | 172 | 13.22 (11.39–15.36) | |
| Heterosexual | 499 (14.6) | 3,236 | 333 | 10.29 (9.24–11.46) | |
| Other | 124 (3.6) | 820 | 61 | 7.44 (5.79–9.56) | |
| HCV (ever) | |||||
| No | 3,026 (88.7) | 21,252 | 2,066 | 9.72 (9.31–10.15) | |
| Yes | 387 (11.3) | 2,670 | 283 | 10.6 (9.43–11.91) | |
| HBsAg (ever) | |||||
| No | 3,269 (95.8) | 22,906 | 2,237 | 9.77 (9.37–10.18) | |
| Yes | 144 (4.2) | 1,015 | 112 | 11.03 (9.17–13.28) | |
| Year HIV Positive | |||||
| <1996 | 1,735 (50.8) | 14,435 | 1,341 | 9.29 (8.81–9.80) | |
| ≥1996 | 1,508 (44.2) | 8,419 | 888 | 10.55 (9.88–11.26) | |
| Missing | 170 (5.0) | 1,067 | 120 | 11.25 (9.40–13.45) | |
| Prior cART2 | |||||
| No | 831 (24.4) | 1,435 | 117 | 8.15 (6.80–9.77) | |
| Yes | 2,582 (75.7) | 22,486 | 2,232 | 9.93 (9.52–10.35) | |
| CD4 cell count (cells/µl)2,3 | |||||
| median (IQR) | 480 (320–665) | ||||
| <200 | 374 (11.0) | 1,669 | 147 | 8.81 (7.49–10.35) | |
| 200–349 | 574 (16.8) | 3,258 | 307 | 9.42 (8.43–10.54) | |
| 350–499 | 807 (23.6) | 4,821 | 398 | 8.26 (7.48–9.11) | |
| ≥500 | 1509 (44.2) | 12,300 | 996 | 8.10 (7.61–8.62) | |
| Missing | 149 (4.4) | 1,873 | 501 | 26.75 (24.51–29.2) | |
| Viral load (copies/ml)2,4 | |||||
| median (IQR) | ≤400 (≤400–8,000) | ||||
| ≤400 | 1910 (56.0) | 16,601 | 1,198 | 7.22 (6.82–7.64) | |
| 401–1,000 | 175 (5.1) | 545 | 50 | 9.18 (6.96–12.11) | |
| 1,001–10,000 | 431 (12.6) | 1,599 | 167 | 10.45 (8.98–12.16) | |
| >10,000 | 759 (22.2) | 3,379 | 392 | 11.60 (10.51–12.81) | |
| Missing | 138 (4.0) | 1,799 | 542 | 30.13 (27.70–32.78) | |
| Calendar Year2 | |||||
| ≤2004 | 2,250 (65.9) | 8,157 | 904 | 11.08 (10.38–11.83) | |
| >2004 | 1,163 (34.1) | 15,765 | 1,445 | 9.17 (8.71–9.65) | |
| Episodes of LTFU5 | |||||
| 0 | 1,781 (52.2) | 20,448 | 1,632 | 7.98 (7.60–8.38) | |
| 1 | 1,126 (33.0) | 2,452 | 506 | 20.63 (18.91–22.51) | |
| ≥2 | 506 (14.8) | 1,021 | 211 | 20.66 (18.05–23.64) | |
1
Loss to follow-up defined as ≥365 days until next clinic visit or prior to death or cohort/site censoring. Patients excluded if censoring or death occurred less than 1 year after enrolment.
2
N=number at enrolment, PY & LTFU & Rate based on time updated value
3
Median CD4 cell count at enrolment=480 cells/µl (interquartile range (IQR) 320–665)
4
Median viral load at enrolment=≤400copies/ml (IQR ≤400–8,000)
5
N=total number ever, PY & LTFU & Rate based on time updated value